D-0271-2019 Class II Terminated

Recalled by Sciegen Pharmaceuticals Inc — Hauppauge, NY

FDA drug recall D-0271-2019 was initiated by Sciegen Pharmaceuticals Inc on Oct 29, 2018 and is designated Class II. Reason for recall: CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product. The recall status is terminated (terminated Sep 25, 2023). Affected quantity: 18,760 HDPE bottles.

Recall details

Product Type
Drugs
Report Date
Nov 28, 2018
Initiation Date
Oct 29, 2018
Termination Date
Sep 25, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
18,760 HDPE bottles

Product description

GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle (NDC 60429-641-90), Rx Only, Manufactured by ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788, Marketed by: GSMS Incorporated Camarillo, CA 93012 USA.

Reason for recall

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Distribution pattern

Nationwide

Code information

60429-641-90 Irbesartan 150mg Tablets, 90 Count Bottle B161003 Sep-19 B161004 Sep-19 B161006 Sep-19 B161007 Sep-19 B161008 Nov-19 B161009 Nov-19 B161010 Nov-19 C161001 Feb-20 C161003 May-20 60429-641-30 Irbesartan 150mg Tablets, 30 Count Bottle GS019526 Nov-19 GS020252 Nov-19 GS020958 Nov-19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0271-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0271-2019. Report a data issue: hello@regdatalab.com.